Metagelan

Metamizole sodium monohydrate, the active ingredient in Metagelan, is a non‑opioid analgesic (pyrazolone derivative) presented as an oral dosage form for oral use. It is used to relieve mild to moderate pain and reduce fever in adults. GNH USA supplies Metagelan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metagelan (metamizole sodium monohydrate) is employed for pain and fever management across several clinical situations.

Mild to moderate pain: provides analgesic relief for conditions such as headache, musculoskeletal pain, or postoperative discomfort. Post‑operative pain: helps control pain after surgical procedures. Colic: alleviates visceral pain associated with colic. Fever: reduces elevated body temperature in febrile states.

Metagelan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Vomiting: occasional episodes. - Dizziness: transient light‑headedness. - Hypotension: mild blood pressure drop. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells, potentially life‑threatening. - Anaphylaxis: acute allergic reaction with airway compromise. - Severe liver injury: rare hepatic dysfunction. - Blood dyscrasias: including thrombocytopenia or hemolytic anemia.

When prescribing Metagelan, consider the following precautions.

Allergy assessment: avoid use in patients with known hypersensitivity to pyrazolones. Blood monitoring: consider periodic complete blood count, especially during prolonged therapy. Renal impairment: use cautiously; dose adjustment may be required. Hepatic dysfunction: monitor liver function tests. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture.

Metagelan can interact with several drug classes; awareness of these interactions helps minimize risk.

Major Interactions (Avoid): - Cytotoxic agents (e.g., cyclophosphamide): increased risk of agranulocytosis. - Immunosuppressants (e.g., azathioprine): additive bone marrow suppression. - Anticoagulants (e.g., warfarin): potential enhancement of bleeding risk.

Moderate Interactions (Monitor Closely): - Alcohol: may increase risk of hypotension and gastrointestinal irritation. - Other NSAIDs: additive gastrointestinal toxicity. - Diuretics: may potentiate hypotensive effect.